Lepu Bio-B (02157) rose more than 7%, rising by about 45% during the month. As of press release, it rose 5.95% to HK$4.63, with a turnover of HK$14.9943 million.
The Zhitong Finance App learned that Lepu Bio-B (02157) rose by more than 7%, rising by about 45% during the month. As of press release, it rose 5.95% to HK$4.63, with a turnover of HK$14.9943 million.
According to the news, Lepu Bio-B announced that Kym, a joint venture with Conoa-B, has signed a license agreement with AstraZeneca to develop and commercialize CMG901. Currently, AstraZeneca has carried out a number of clinical studies on CMG901 treatment for advanced solid tumors. It is reported that in February 2023, KYM signed a license agreement with AstraZeneca to develop and commercialize the CMG901.
Notably, due to breakthroughs in business development and commercialization, Lepu Biotech's revenue in 2023 soared by 1347% to 225 million yuan. Huachuang Securities pointed out that Lepu Biotech has abundant ADC pipelines, and the PD-1 monoclonal antibody, pritrizumab is already on the market. Through combined use with a wide range of ADC drug candidates, it is expected to fully realize the pipeline value in the IO+ADC wave.